Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.62 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ESRRG | P62508 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12067341 | 0.94 | SIRT1 (0.71) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28662121 | 0.91 | SIRT1 (0.68) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16677197 | 0.88 | MIF (0.66) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16677195 | 0.88 | SIRT1 (0.65) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12940302 | 0.88 | SIRT1 (0.65) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2344788 | 0.88 | KMT2A (0.68) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2344078 | 0.87 | SIRT1 (0.64) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28330757 | 0.87 | SIRT1 (0.64) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3400605 | 0.87 | SIRT1 (0.64) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL907336 | 0.87 | SIRT1 (0.64) | SIRT1MAPTALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302863-A1 | USE OF THBS1 INHIBITOR FOR OVERCOMING DRUG RESISTANCE IN CANCER | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-10-02 | — | — | US | claimed |
| US-20250235446-A1 | COMPOSITION FOR INHIBITING METASTASIS AND ENHANCING ANTICANCER DRUG SENSITIVITY | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-07-24 | — | — | US | claimed |
| WO-2024196963-A2 | COMPOSITIONS AND METHODS FOR GENOME EDITING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-26 | — | — | WO | claimed |
| EP-4424327-A1 | METHOD OR AGENT WITH HDAC REGULATOR, FOR TREATMENT OF DIABETES AND COMPLICATIONS | Biozipcode, Inc. (JP) | 2024-09-04 | — | — | EP | claimed |
| CN-118475370-A | Methods or agents for treating diabetes and complications based on HDAC modulators | 比奥兹普科德公司 | 2024-08-09 | — | — | CN | claimed |
| EP-4362968-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2024-05-08 | — | — | EP | claimed |
| CN-117915938-A | Methods and compositions for inhibiting dihydroorotate dehydrogenase in combination with anti-CD 47-sirpa therapeutic agents | 俄亥俄州国家创新基金会 | 2024-04-19 | — | — | CN | claimed |
| US-20230372293-A1 | SIRT1 INHIBITOR OR ANTAGONIST FOR USE IN PREVENTING AND/OR TREATING AN HPV INDUCED TUMOUR | UNIVERSITA' DEGLI STUDI DEL PIEMONTE ORIENTALE "A. AVOGADRO" (IT) | 2023-11-23 | — | — | US | claimed |
| EP-4272739-A1 | COMPOSITION FOR INHIBITING METASTASIS AND ENHANCING ANTICANCER DRUG SENSITIVITY | Korea Advanced Institute of Science and Technology (KR) | 2023-11-08 | — | — | EP | claimed |
| US-20230314448-A1 | METHODS OF TREATING PATIENTS AT RISK FOR RENAL INJURY AND RENAL FAILURE | RENIBUS THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | US | claimed |
| EP-4060025-A1 | PREPARATION METHOD FOR OLFACTORY PRECURSOR CELL | Beijing Hongtianji Neuroscience Academy (CN) | 2022-09-21 | — | — | EP | claimed |
| WO-2022146025-A1 | COMPOSITION FOR INHIBITING METASTASIS AND ENHANCING ANTICANCER DRUG SENSITIVITY | 한국과학기술원 | 2022-07-07 | — | — | WO | claimed |
| WO-2022070161-A1 | SIRT1 INHIBITOR OR ANTAGONIST FOR USE IN PREVENTING AND/OR TREATING AN HPV INDUCED TUMOUR | UNIVERSITA' DEGLI STUDI DEL PIEMONTE ORIENTALE "A. AVOGADRO" (IT) | 2022-04-07 | — | — | WO | claimed |
| WO-2022026806-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | UNIVERSITY OF CONNECTICUT (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-03 | — | — | US | claimed |
| CN-113582969-A | Application of acylthiourea compound in preparation of anti-enterovirus drugs | 武汉大学 | 2021-11-02 | — | — | CN | claimed |
| US-9168316-B2 | Methods for treating obesity | GU YANSONG (US) | 2015-10-27 | — | — | US | claimed |
| US-20140322136-A1 | METHODS FOR TREATING OBESITY | GU YANSONG (US) | 2014-10-30 | — | — | US | claimed |
| US-20110262362-A1 | METHODS FOR TREATING OBESITY | GU YANSONG | 2011-10-27 | — | — | US | claimed |
| WO-2010042868-A2 | METHODS FOR TREATING OBESITY | UNIVERSITY OF WASHINGTON (US) | 2010-04-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL2, BCL2L2, BCL2L1 | SIRT1 360/4885MAPT 718/4885ALDH1A1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.